News in brief

Dr. Reddy’s stock shares rises amid recent US FDA citations

By Maggie Lynch

- Last updated on GMT

(Image: Getty/monsitj)
(Image: Getty/monsitj)

Related tags Stock exchange Stock market Fda Form 483 India

Dr. Reddy’s Laboratories site in Visakhapatnam, India, was issued a Form 483 last month, yet shares rose after a more recent audit where zero observations were noted.

The company’s shares rose 3%​ in early trading on November 19, after an audit of the company’s site by the US Food and Drug Administration (FDA) in Andhra Pradesh, India, saw zero observations.

In a Bombay Stock Exchange filing, Dr. Reddy’s stated that the audit of its Formulations Srikakulum Plant Unit II received zero observations. The filing occurred during post-market hours on Friday, the following Monday shares jumped.

Between October 22 and October 30, 2018, however, Dr. Reddy’s site in Visakhapatnam, India, was observed by the FDA and it noted ten observations that led to the issuing of a Form 483 for its site. The observations generally regarded the Quality Unit and proper implementations to maintain sterile products.

The FDA states on its website that a Form 483​ is distributed at the conclusion of an inspection when observations regarding conditions that may constitute violations to the Food Drug and Cosmetic Act are seen.

The company’s Duvvada​ site, which primarily manufactures generic chemotherapy treatments, was issued a Form 483. A site in Bollaram​ and another in Jinneram Mandal​ were also recently given observations following audits.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more